TIL Overview

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

Wall Street analysts forecast TIL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Instil Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased

Instil Bio Inc. EPS for the last quarter amounts to -1.21 USD, decreased -33.52

Instil Bio Inc (TIL) has 14 emplpoyees as of March 31 2026.

Today TIL has the market capitalization of 54.05M USD.